Aprovel, mbadamba 150 mg, pcs iri na anọ.

Biko, tupu ịzụrụ Aprovel, mbadamba 150 mg, pcs iri na anọ., Lelee ozi banyere ya na ozi dị na weebụsaịtị webụsaịtị nke onye na-emepụta ma ọ bụ depụta nkọwapụta nke otu ụdị na onye njikwa ụlọ ọrụ anyị!

Ozi a gosiputara na saịtị ahụ abụghị onyinye ọha. Onye rụpụtara ya nwere ikike ịme mgbanwe n ’okike, imewe na ịkwakọ ngwaahịa. Ihe osise ngwaahịa na foto nke ewepụtara na katalọgụ saịtị ahụ nwere ike ịdị iche na mbido mbụ.

Ozi banyere ọnụahịa nke egosiri na katalọgụ saịtị ahụ nwere ike ịdị iche na nke dị n'oge ahụ na-etinye iwu maka ngwaahịa kwekọrọ.

Omume ọgwụ

Ugbo: angiotensin II onye na - anabata ihe.
Ihe ndị a na-ahụ maka ọgwụ: Aprovel bụ ọgwụ antihypertensive, ihe na-emegide nke ndị na-anabata angiotensin II (ụdị AT1).
Irbesartan bụ onye dị ike, na-arụ ọrụ mgbe a na-ewere ya dị ka onye na - ahọrọ antiotistin II receptor antagonist (ụdị AT1). Ọ na - egbochi mmetụta physiologically dị egwu nke angiotensin II, mezuru site na ndị na - anabata ndị ọbịa nke ụdị AT1, n'agbanyeghị isi iyi ma ọ bụ ụzọ njikọta nke angiotensin II. Mmetụta izizi ụfọdụ nke ndị na-anabata angiotensin II (AT1) na-eduga na mmụba nke plasma nke renin na angiotensin II na mbelata plasma nke mkpokọta aldosterone. Mgbe ị na-eji ọgwụ ndị a tụrụ aro ya, ntụtụ nke ion potassium adịghị agbanwe nke ukwuu. Irbesartan anaghị egbochi enzyme kininase-II (angiotensin na-agbanwe enzyme), site na enyemaka nke usoro nke angiotensin II na mbibi nke bradykinin na metabolites na-adịghị arụ ọrụ na-apụta. Maka ngosipụta nke ihe irbesartan, a chọghị ịgbalite metabolic ya.
Irbesartan na-agbada ọbara mgbali elu (BP) na obere mgbanwe mgbanwe obi. Mgbe ewere ya na onunu ogwu ruru 300 mg otu ugboro kwa ụbọchị, mbelata ọbara mgbali bụ nke dabere na okike, agbanyeghị na ịbawanye ụba nke irbesartan, mmụba nke mmetụta hypotensive enweghị uru.
A na-enweta mbelata ọbara mgbali elu ka awa 3-6 gachara mgbe mmesịrị, mmetụta antihypertensive na-adịgide ọ dịkarịa ala awa 24. Abalị iri abụọ na anọ gachara ọgwụ irbesartan tụrụ aro, mbelata ọbara mgbali elu bụ 60-70% ma e jiri ya mee ihe kachasị mma banyere ọgwụ site n'akụkụ diastolic na ọbara mgbali systolic. Mgbe ewere ya otu ugboro kwa ụbọchị na ọgwụ nke 150-300 mg, ọnụego mbelata ọbara mgbali elu site na njedebe nke etiti interdose (i.e., awa 24 mgbe ị theụsịrị ọgwụ ahụ) n'ọnọdụ onye ọrịa dina ma ọ bụ ịnọdụ na nkezi na 8-13 / 5-8 mm RT .art. (systolic / diastolic ọbara mgbali) dị ukwuu karịa nke pilasibo.
Theụ ọgwụ ahụ otu nha 150 mg otu ugboro n’ụbọchị na-akpata otu ihe ahụ na - emeghachi omume (iwetulata ọbara mgbali elu tupu ị takingụ ọgwụ ọzọ nke ọgwụ ahụ na mbelata ọbara mgbali n’ime awa 24) ka ị takingụ otu ọgwụ ahụ ụzọ abụọ.
Mmetụta hypotensive nke ọgwụ Aprovel na-etolite n'ime izu 1-2, a na-enwetakwa mmetụta ọgwụgwọ kachasị maka izu 4-6 ka mmalite nke ọgwụgwọ. Mmetụta antihypertensive megide ndabere nke ọgwụgwọ ogologo oge ka dịgidere. Mgbe ịkwụsị ọrụ ọgwụgwọ, ọbara mgbali ji nwayọọ nwayọọ na-alaghachi uru mbụ ọ bara. Mgbe akagbuo ọgwụ a, o nweghi oria ana ewepu.
Apdị irè nke ọgwụ Aprovel anaghị adabere afọ na okike. Ndị ọrịa nke agbụrụ Negroid enwechaghị azaghachi ọgwụgwọ Aprovel (dịka ọgwụ ndị ọzọ na-emetụta usoro renin-angiotensin-aldosterone).
Irbesartan anaghị emetụta ọgwụgwọ seric uric acid ma ọ bụ urinary uric acid excretion.
Pharmacokinetics: Mgbe nchịkwa ọnụ gasịrị, irbesartan na-abanyekwa nke ọma, bioavailability ya zuru oke bụ ihe dị ka 60-80%. Na imekọ nri oge anaghị emetụta oke bioav adị nke irbesartan.
Nkwurịta okwu na protein ndị na-edozi ahụ bụ ihe dịka 96%. Jikọtara ihe ndị mejupụtara ọbara ọbara abaghị uru. Olu nke nkesa bụ lita 53-93.
Mgbe nchịkwa ọnụ ma ọ bụ nchịkwa ọgbụgba nke 14C-irbesartan, 80-85% nke redioachibido plasma na-ekesa na-apụta na irbesartan na-agbanweghị. Irbesartan na-eme ka imeju metọọkwa ya site na iji mmiri na-agbaze agbaze yana glucuronic acid. A na-eme oxidation nke irbesartan tumadi site na enyemaka nke cytochrome P450 CYP2C9, ntinye nke isoenzyme CYP3A4 na metabolism nke irbesartan abaghị uru. Ihe metabolite bụ isi na sisitemu sistem bụ irbesartan glucuronide (ihe dịka 6%).
Irbesartan nwere pharmacokinetics dị larịị na nke kwesiri ya n’ogo onunu site na 10 ruo 600 mg, na usoro onunu ogwu kariri 600 mg (nke ugboro abụọ a na-atụ aro ya ka ukwuu), kinetics nke irbesartan ghọrọ nke na - abụghị linear (belata na mmịpụta). Mgbe nchịkwa ọnụ gasịrị, a na-enweta ihe kachasị plasma mgbe awa 1.5-2 gasịrị. Mkpokọta mkpochapụ na mkpochapụ bụ 157-176 na 3-3.5 ml / min., Dika. Oge ndụ ọkara ikpeazụ nke irbesartan bụ awa 11-15. N'iji otu ubochi kwa ụbọchị, a na-enweta ntụpọ plasma ịta ahụhụ (Css) mgbe ụbọchị atọ gachara. Site na iji irbesartan kwa ụbọchị otu ugboro, a na-ahụta oke pere mpe na plasma ọbara (ihe na-erughị 20%). Mụ nwanyị (ma e jiri ya tụnyere ụmụ nwoke) nwere plasma plasma nke irbesartan. Agbanyeghị, achọpụtaghị ọdịiche dị n'etiti nwoke na nwanyị na ọkara ndụ na nnakọta nke irbesartan. Uzo a ghaghi idozi udiri irbesartan na umu nwanyi. Ofkpụrụ nke AUC (mpaghara n'okpuru oge ịta ahụhụ pharmacokinetic) na Cmax (oke plasma ịta) nke irbesartan n'ime ndị ọrịa agadi (≥65 afọ) dịtụ elu karịa na ndị ọrịa dị obere, n'agbanyeghị, ọkara ndụ ikpeazụ ha adịghị iche nke ukwuu. Ọchọghị ime mgbanwe na ndị ọrịa agadi.
A na-ahụpụ Irbesartan na metabolites ya n'ahụ, yana ma ọ bụ mmamịrị na mmamịrị. Mgbe usoro nchịkwa ọnụ ma ọ bụ nchịkwa intraven 14C-irbesartan, ihe dị ka 20% nke redioaktivu na-ahụ na mmamịrị ahụ, ma nke ọzọ na feces. Ihe na-erughị 2% nke nchịkwa a na-apụ apụ na mmamịrị dịka irbesartan na-agbanweghị.
Ọrụ ndị na-arụ ọrụ na-arụ ọrụ ezumike nká: N’ebe ndị ọrịa na-arụ ọrụ ezumike mkpirisi ma ọ bụ ndị ọrịa na-anwale hemodialysis, ọgwụ ọgwụ nke irbesartan adịghị agbanwe agbanwe. Ewepughi Irbesartan ahu n’ahu mgbe obula.
Ọrụ imeju na - arụ ọrụ: N’ebe ndị ọrịa nwere ọrịa imeju na - adị nfe ma ọ bụ na - agafeghị oke, a naghị agbanwe usoro ọgwụ pharmacookinetic nke irbesartan. Emebeghị nnyocha Pharmacokinetic na ndị ọrịa nwere nnukwu ọrịa ịba ọcha n'anya.

• Ọbara mgbali dị mkpa
• Nephropathy nwere ọbara mgbali elu na ụdị ọrịa shuga mellitus 2 (dị ka akụkụ nke usoro ọgwụgwọ antihypertensive).

Nsonaazụ

N'ime ihe ọmụmụ na-achịkwa placebo (ndị ọrịa 1965 natara irbesartan), a chọpụtara ihe mmeghachi omume na-esote.
Site n'akụkụ nke usoro ụjọ ahụ: ọ na - abụkarị akpịrị.
Site na sisitemu obi: oge ​​ufodu - tachycardia, oria di oku.
Site na usoro iku ume: oge ​​ụfọdụ - ụkwara.
Site na usoro digestive: oge ​​- ọgbụgbọ, ọgbụgbọ, mgbe ụfọdụ - afọ ọsịsa, dyspepsia, obi mgbawa.
Site na usoro ọmụmụ: oge ​​ụfọdụ - agụụ mmekọahụ.
N’akụkụ ahụ dị ka dum: ike gwụkarịsịrị, mgbe ụfọdụ obi mgbu.
Na akụkụ nke egosi ụlọ nyocha: oge ​​- mmụba dị ukwuu na KFK (1.7%), esiteghị na ngosipụta ọgwụgwọ nke usoro akwara ahụ.
N'ime ndị ọrịa nwere ọbara mgbali elu na ụdị ọrịa shuga 2 mellitus na microalbuminuria nke nwere ọrụ mkpo nkịtị, a hụrụ orthostatic dizziness na orthostatic hypotension na 0,5% nke ndị ọrịa (karịa karịa na placebo). N'ime ndị ọrịa nwere ọrịa mellitus nke nwere ọbara mgbali elu na microalbuminuria na ọrụ nkịtị na-arụ ọrụ, a na-ahụ hyperkalemia (karịa 5.5% mmol / L) na 29.4% nke ndị ọrịa na otu na-enweta 300 mg irbesartan na 22% nke ndị ọrịa na otu placebo.
N'ime ndị ọrịa nwere ọbara mgbali elu na ọrịa shuga mellitus, ọdịda akụrụ na-adịghị ala ala na proteinuria siri ike na 2% nke ndị ọrịa, a chọpụtara mmeghachi omume ndị ọzọ na-esote (karịa mgbe enwere ya).
Site n'akụkụ nke usoro ụjọ ahụ nke etiti: ọtụtụ mgbe - orthostatic dizziness.
Site na sisitemu obi: otutu mgbe - orthostatic hypotension.
Site na usoro akwara: mgbe mgbe - ihe mgbu n’ọkpụkpụ na akwara.
N'akụkụ nke ụlọ nyocha: hyperkalemia (ihe karịrị 5.5% mmol / l) mere na 46.3% nke ndị ọrịa na otu ndị ọrịa na-anata irbesartan, na 26.3% nke ndị ọrịa nọ na ìgwè ahụ. Mbelata hemoglobin, nke na-adịchaghị mkpa ọgwụgwọ, ka a chọpụtara na 1.7% ndị ọrịa na-anata irbesartan.
Achọpụtara mmeghachi omume ọjọọ ndị a na oge azụmaahịa:
Mmeghachi omume nfụkasị ahụ: ọ na - adịkarịghị - ihe ọkụ, urticaria, angioedema (dịka ya na ndị ọzọ na - anabata antagonists II angiotensin II).
Site n'akụkụ nke metabolism: ọ na - adịkarịghị - hyperkalemia.
Site n'akụkụ nke sistemụ akwara: ọ dịkarịsịrị - isi ọwụwa, na-akụ ntị.
Site na usoro nri: dịkarịsịrị - dyspepsia, ọrụ imeju na - arụ ọrụ, ịba ọcha n'anya.
Site na usoro akwara: ike adịkarịghị - myalgia, arthralgia.
Site na usoro urinary: dịkarịsịrị - arụ ọrụ na-arụ ọrụ na-arụ ọrụ nke ọma (gụnyere okwu ndị dịpụrụ adịpụ nke akụrụ gbasara akụrụ na ndị ọrịa nwere ike ịrịa)

Ntụziaka pụrụ iche

Na akpachapụ anya, Aprovel kwesịrị ka e nye ndị ọrịa nwere nsogbu akwara mkpọnwụ akwara n'ihi ihe egwu enwere ike ibute ọgbụgba na nnukwu akwara akwara.
Tupu nhọpụta nke ọgwụ Aprovel nke ọgwụ na diuretics na oke onunu nwere ike ibute akpọnwụ akpukpo ma nwekwuo ohere nke hypotension na mbido ọgwụgwọ Aprovel. N’ebe ndị ọrịa akpọnwụ akpọnwụ nọ ma ọ bụ n’arụ ọrịa nke sodium ion n’ihi mmụba kpụ ọkụ n’ọnụ n’arụ, igbochi nnu n’ime nri, afọ ọsịsa ma ọ bụ ọgbụgbọ na ọgbụgba, yana ndị ọrịa n’arụ ọ̀gụrụ, ịtụgharị ọ̀gù n’ịchebe mbelata ya dị mkpa.
Nsonaazụ nke ihe omumu
N'ime ihe omumu emere na anumanu ulo nyocha, anaghi egosiputa mutagenic, clastogenic na carcinogenic nke Aprovel.
Iji Ọrịa edimụaka
Emebebeghị nchekwa na ịdị mma nke ọgwụ a na ụmụaka.
Mmetụta ikike ịkwọ ụgbọ ala na usoro nchịkwa
Onweghi ihe ngosi nke iwere Aprovel n’ikike inya ugboala ma obu igwe eji eme ihe.